MesaGreen Pharmaceutical Company Files an Investigational New Animal Drug Application
FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…
Mesa Science Associates Receives Grant to Begin Study of a Treatment for Marfan Syndrome
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…
NIH SBIR Grant application 1/5/2022
Mesa Science Associates has applied for an NIH Small Business Innovative Research (SBIR) Grant from the National Institutes of Health…
Mesa Green Caine Study Results Reported at Epilepsy Conference
Mesa Science Associates Inc. (MSA) and Mesa Green Pharma LLC (MGP) are pleased to announce the results of a study…
Mesa Green Pharma LLC Receives Positive Feedback from FDA’s Center for Veterinary Medicine
Pilot Study Provides Positive Results for K9MGP Treatment Active Canine Seizures FREDERICK, Md. September 21,2021— Mr. Michael Mesa, CEO of…
Thank You MSA
August 13, 2021 – This summer, I was able to intern for Mesa Science Associates (MSA). During my tireless search…
Dr. Kenneth Dretchen PhD continues appointment for year 2 as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Discovery Research Award Committee
May 2021 This prestigious committee will review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches…
MesaGreen Announces Progress
K9MGP Seizure Program In July 2019, MesaGreen Pharmaceutical (MGP) entered into a research agreement with the University of Minnesota Schools…
MSA Intern Graduates
Mesa Science Associates is pleased to announce that Peyton Coady, a former intern at MSA will be graduating from James…
Progress During the Pandemic
Our surviving the Covid-19 experience has been an example of what having a great team can do for a company….
MSA News
Nov
10,
2022
MesaGreen Pharmaceutical Company Files an Investigational New Animal Drug Application
FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…
Jul
18,
2022
Mesa Science Associates Receives Grant to Begin Study of a Treatment for Marfan Syndrome
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…
Jan
14,
2022
NIH SBIR Grant application 1/5/2022
Mesa Science Associates has applied for an NIH Small Business Innovative Research (SBIR) Grant from the National Institutes of Health…
